AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32446880 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent support program without boosters (PGNB)
Number of subjects: 174
Study 32446880 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent support program with boosters (PGB)
Number of subjects: 174
Study 32446880 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (ST)
Number of subjects: 174
Study 34775581 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained uterine compression (group 1)
Number of subjects: 550
Study 34775581 — intervention group
Group type: COMPARATOR
Intervention: Uterine massage (group 2)
Number of subjects: 550
Study 34647961 — intervention group
Group type: EXPERIMENTAL
Intervention: Active supplement (125 mg L‐lysine, 40 mg vitamin C, 26.3 mg Vitis vinifera extract, 5 mg zinc, 100 mg Citrus aurantium)
Number of subjects: 61
Study 34647961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 34647961 — intervention group
Group type: EXPERIMENTAL
Intervention: Active supplement
Number of subjects: 61
Study 33009241 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan 5/80 mg FDC
Number of subjects: 42
Study 33009241 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 160 mg monotherapy
Number of subjects: 42
Study 33775867 — intervention group
Group type: EXPERIMENTAL
Intervention: LCMUFA oil (saury oil)
Number of subjects: 60
Study 33775867 — intervention group
Group type: EXPERIMENTAL
Intervention: C20:1 and C22:1 oils
Number of subjects: 60
Study 33109240 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (20 mg biweekly if < 30 kg or 40 mg biweekly if ≥ 30 kg)
Number of subjects: 118
Study 33109240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 36171463 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS stimulation
Number of subjects: 36
Study 36171463 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 36
Study 34214210 — intervention group
Group type: EXPERIMENTAL
Intervention: Perhexiline (150-600 ng/mL)
Number of subjects: 113
Study 34214210 — intervention group
Group type: EXPERIMENTAL
Intervention: Perhexiline (therapeutic concentrations)
Number of subjects: 113
Study 34214210 — intervention group
Group type: EXPERIMENTAL
Intervention: Perhexiline (supratherapeutic concentrations)
Number of subjects: 113
Study 34214210 — intervention group
Group type: EXPERIMENTAL
Intervention: Perhexiline
Number of subjects: 113
Study 35404074 — intervention group
Group type: COMPARATOR
Intervention: GST‐HG131 10-300 mg (single ascending dose)
Number of subjects: 100
Study 35404074 — intervention group
Group type: COMPARATOR
Intervention: GST‐HG131 30-60 mg BID (multiple ascending dose)
Number of subjects: 100
Study 35404074 — intervention group
Group type: COMPARATOR
Intervention: GST‐HG131 100 mg (multiple ascending dose)
Number of subjects: 100
Study 35404074 — intervention group
Group type: COMPARATOR
Intervention: GST‐HG131 100 mg (food effect)
Number of subjects: 100
Study 34426442 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) with ritonavir (cohort 1)
Number of subjects: 40
Study 34426442 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) with itraconazole (cohort 2)
Number of subjects: 40
Study 34426442 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab deruxtecan (T-DXd)
Number of subjects: 40
Study 32736164 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a caregiver
Number of subjects: 210
Study 34111245 — intervention group
Group type: EXPERIMENTAL
Intervention: Postexercise recovery in patients with confirmed peripheral neuropathy
Number of subjects: 0
Study 34111245 — intervention group
Group type: EXPERIMENTAL
Intervention: Postexercise recovery in patients with subclinical peripheral neuropathy
Number of subjects: 0
Study 34111245 — intervention group
Group type: COMPARATOR
Intervention: Postexercise recovery in healthy controls
Number of subjects: 0
Study 34111245 — intervention group
Group type: COMPARATOR
Intervention: Postexercise recovery in patients with obesity
Number of subjects: 0
Study 34111245 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide-dependent function in confirmed peripheral neuropathy
Number of subjects: 0
Study 34111245 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide-independent function in confirmed peripheral neuropathy
Number of subjects: 0
Study 34111245 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurogenic contribution in confirmed peripheral neuropathy
Number of subjects: 0
Study 35490165 — intervention group
Group type: EXPERIMENTAL
Intervention: JDE exercise program for 12 weeks, twice a week for 45 minutes each
Number of subjects: 59
Study 35490165 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 59
Study 33475762 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic enucleation of the prostate (EEP) using plasmakinetic or diode-based techniques
Number of subjects: 458
Study 35203087 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 4 µg/kg
Number of subjects: 115
Study 35203087 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 0.5 mg/kg
Number of subjects: 115
Study 32614361 — intervention group
Group type: EXPERIMENTAL
Intervention: AqualiefTM (carnosine and dried calyces of Hibiscus sabdariffa L.)
Number of subjects: 60
Study 32614361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 35190424 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mA anodal tDCS targeted to the affected UE motor map during HABIT sessions
Number of subjects: 81
Study 35190424 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mA cathodal tDCS to the contralesional motor cortex during HABIT sessions
Number of subjects: 81
Study 35190424 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS during HABIT sessions
Number of subjects: 81
Study 33741216 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support specialists (PSS)
Number of subjects: 680
Study 33741216 — intervention group
Group type: COMPARATOR
Intervention: Facilitated local change team (LCT) intervention
Number of subjects: 680
Study 34871204 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (DCB)
Number of subjects: 0
Study 36056372 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic case management with health coaching (ECM+)
Number of subjects: 0
Study 36056372 — intervention group
Group type: COMPARATOR
Intervention: Health coaching alone (HC)
Number of subjects: 0
Study 34375023 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic CCTA (87 patients)
Number of subjects: 164
Study 34375023 — intervention group
Group type: COMPARATOR
Intervention: Standard CCTA (77 patients)
Number of subjects: 164
Study 33131126 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant allergen immunotherapy (AIT)
Number of subjects: 14
Study 33131126 — intervention group
Group type: COMPARATOR
Intervention: Control (non-AIT group)
Number of subjects: 14
Study 35763249 — intervention group
Group type: EXPERIMENTAL
Intervention: SBRT + Abiraterone acetate 1000 mg and oral prednisone 10 mg daily
Number of subjects: 42
Study 35763249 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (GnRH agonist or antagonist plus abiraterone acetate 1000 mg and oral prednisone 10 mg daily)
Number of subjects: 42
Study 35763249 — intervention group
Group type: EXPERIMENTAL
Intervention: SBRT + Abiraterone
Number of subjects: 42
Study 35763249 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 42
Study 35763249 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 42
Study 32693855 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly nutrition education and counselling (NEC) during pregnancy and infancy period
Number of subjects: 438
Study 32693855 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 438
Study 32267032 — intervention group
Group type: EXPERIMENTAL
Intervention: Short intervals (SI: 30-seconds)
Number of subjects: 8
Study 35295776 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal pathways to care, education and training program for professionals, systematic screening for children
Number of subjects: 20
Study 35295776 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific implementation support)
Number of subjects: 20
Study 32000514 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive ablation
Number of subjects: 159
Study 32000514 — intervention group
Group type: COMPARATOR
Intervention: Deferred ablation
Number of subjects: 159
Study 34057183 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg/kg bolus at induction, followed by 0.6 μg/kg/h infusion until emergence), n = 75
Number of subjects: 369
Study 34057183 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion, n = 75
Number of subjects: 369
Study 34753183 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Intervention (EI) program
Number of subjects: 818
Study 34753183 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT), Occupational Therapy (OT), Speech Therapy (ST)
Number of subjects: 818
Study 34753183 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal characteristics and state of enrollment
Number of subjects: 818
Study 32517392 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation (SCS)
Number of subjects: 63
Study 32517392 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Radiofrequency (PRF)
Number of subjects: 63
Study 36339169 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity tracker with Personal Activity Intelligence (PAI)
Number of subjects: 180
Study 36339169 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity tracker with PAI and access to online training videos (Les Mills+)
Number of subjects: 180
Study 36339169 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity tracker with PAI, home-based online training, and additional peer support via social media
Number of subjects: 180
Study 36339169 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 180
Study 34259399 — intervention group
Group type: EXPERIMENTAL
Intervention: Yin-yang penetrating acupuncture with elongated needle
Number of subjects: 60
Study 34259399 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture
Number of subjects: 60
Study 32779001 — intervention group
Group type: EXPERIMENTAL
Intervention: β1 + 2 AR antagonist (nadolol)
Number of subjects: 12
Study 32779001 — intervention group
Group type: EXPERIMENTAL
Intervention: β1 AR antagonist (bisoprolol)
Number of subjects: 12
Study 32779001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 35569763 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal 1.0 mg risuteganib
Number of subjects: 39
Study 35569763 — intervention group
Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 39
Study 33707988 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 s × 3 times
Number of subjects: 45
Study 33707988 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 s × 10 times
Number of subjects: 45
Study 33707988 — intervention group
Group type: COMPARATOR
Intervention: 30 s × 1 time
Number of subjects: 45
Study 33707988 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 45
Study 32883371 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen alone
Number of subjects: 0
Study 32883371 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen in combination with acetaminophen
Number of subjects: 0
Study 32883371 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen in combination with hydromorphone
Number of subjects: 0
Study 32883371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32883371 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen alone, Ibuprofen + Acetaminophen, Ibuprofen + Hydromorphone
Number of subjects: 0
Study 32883371 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Opioid trial
Number of subjects: 0
Study 32186924 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers and Babies Course (a six-week Spanish cognitive behavioural therapy group intervention)
Number of subjects: 86
Study 36278293 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (Zhejiang Xianju Pharmaceutical Co., Ltd., China)
Number of subjects: 56
Study 36278293 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (Medrol, Pfizer Italia SRL)
Number of subjects: 56
Study 36278293 — intervention group
Group type: EXPERIMENTAL
Intervention: Both test and reference formulations
Number of subjects: 56
Study 33113088 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent trastuzumab and chemotherapy
Number of subjects: 1843
Study 33113088 — intervention group
Group type: COMPARATOR
Intervention: Sequential trastuzumab after chemotherapy
Number of subjects: 1843
Study 32998696 — intervention group
Group type: EXPERIMENTAL
Intervention: lncRNA expression analysis during HFs cycle
Number of subjects: 2884
Study 32998696 — intervention group
Group type: EXPERIMENTAL
Intervention: GO and KEGG enrichment analysis of DELs
Number of subjects: 2884
Study 32998696 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparative analysis of DELs with cashmere goat lncRNA-seq data
Number of subjects: 2884
Study 35564330 — intervention group
Group type: EXPERIMENTAL
Intervention: Satir Transformational Systemic Therapy (STST) group counseling intervention
Number of subjects: 60
Study 35564330 — intervention group
Group type: COMPARATOR
Intervention: Control/no treatment
Number of subjects: 60
Study 34639313 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-rehabilitation with VAPA
Number of subjects: 29
Study 34639313 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study 34759287 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 112
Study 32571334 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy diets
Number of subjects: 0
Study 32571334 — intervention group
Group type: COMPARATOR
Intervention: Unhealthy diets
Number of subjects: 0
Study 32571334 — intervention group
Group type: EXPERIMENTAL
Intervention: Food costs
Number of subjects: 0
Study 35956281 — intervention group
Group type: EXPERIMENTAL
Intervention: Early introduction of solid foods (10‐12th week corrected age)
Number of subjects: 177
Study 35956281 — intervention group
Group type: COMPARATOR
Intervention: Late introduction of solid foods (16‐18th week corrected age)
Number of subjects: 177
Study 34339686 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 0
Study 36498087 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal wall block (AWB)
Number of subjects: 64
Study 36498087 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (Control group)
Number of subjects: 64
Study 33582295 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile mental health platform
Number of subjects: 7884
Study 33582295 — intervention group
Group type: COMPARATOR
Intervention: Referral to usual care
Number of subjects: 7884
Study 32456236 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention consisting of green vegetables, beef, whole milk, and butter for 6 months.
Number of subjects: 62
Study 32456236 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no treatment) as control group.
Number of subjects: 62
Study 35109960 — intervention group
Group type: EXPERIMENTAL
Intervention: Montmorency cherries (30 ml twice daily)
Number of subjects: 50
Study 34558312 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 112
Study 34558312 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 112
Study 35672660 — intervention group
Group type: EXPERIMENTAL
Intervention: DexP group (60 µg of dexmedetomidine added to ropivacaine)
Number of subjects: 60
Study 35672660 — intervention group
Group type: EXPERIMENTAL
Intervention: DexIV group (systemic-only dexmedetomidine)
Number of subjects: 60
Study 35672660 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal saline as a placebo)
Number of subjects: 60
Study 35672660 — intervention group
Group type: EXPERIMENTAL
Intervention: DexP and DexIV groups
Number of subjects: 60
Study 33208662 — intervention group
Group type: EXPERIMENTAL
Intervention: Elasticized longitudinal stockinette (ELS)
Number of subjects: 25
Study 33208662 — intervention group
Group type: EXPERIMENTAL
Intervention: Elasticized tubular bandage (ETB)
Number of subjects: 25
Study 33208662 — intervention group
Group type: COMPARATOR
Intervention: Both ELS and ETB
Number of subjects: 25
Study 34569482 — intervention group
Group type: EXPERIMENTAL
Intervention: Molidustat (25 mg or 50 mg once daily)
Number of subjects: 164
Study 34569482 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin (darbepoetin alfa, injected subcutaneously once every 2 or 4 weeks)
Number of subjects: 164
Study 34569482 — intervention group
Group type: EXPERIMENTAL
Intervention: Molidustat
Number of subjects: 164
Study 34569482 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin
Number of subjects: 164
Study 32398710 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive Therapy (MCT)
Number of subjects: 174
Study 32398710 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 174
Study 37420186 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days of oestrogen priming (group A)
Number of subjects: 144
Study 37420186 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 days of oestrogen priming (group B)
Number of subjects: 144
Study 34446477 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital diabetes prevention intervention (mobile app)
Number of subjects: 100
Study 34446477 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app (beta testing)
Number of subjects: 100
Study 32067633 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (∼20 mg/kg)
Number of subjects: 1200
Study 32067633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200
Study 35907825 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified paramedian technique (group PM)
Number of subjects: 150
Study 34292493 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA (100 U)
Number of subjects: 248
Study 34292493 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 248
Study 32825595 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined fitness training
Number of subjects: 113
Study 32825595 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration training
Number of subjects: 113
Study 32825595 — intervention group
Group type: COMPARATOR
Intervention: Control group (cessation of training)
Number of subjects: 113
Study 36326604 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin, 10 mg per day
Number of subjects: 6262
Study 36326604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6262
Study 32938561 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of comorbidities (evaluated using the updated Charlson comorbidity index)
Number of subjects: 136
Study 32938561 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly patients
Number of subjects: 136
Study 32938561 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with congestive heart failure
Number of subjects: 136
Study 32938561 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with dementia
Number of subjects: 136
Study 32938561 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with hemiplegia/paraplegia
Number of subjects: 136
Study 32938561 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with renal disease
Number of subjects: 136
Study 32938561 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor grade
Number of subjects: 136
Study 32938561 — intervention group
Group type: EXPERIMENTAL
Intervention: Updated Charlson comorbidity index
Number of subjects: 136
Study 32951241 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-mixed nitrous oxide/oxygen mixture treatment
Number of subjects: 200
Study 32951241 — intervention group
Group type: COMPARATOR
Intervention: Medical air treatment
Number of subjects: 200
Study 35709798 — intervention group
Group type: COMPARATOR
Intervention: Unadjuvanted PXVX0317 (2×20 μg)
Number of subjects: 415
Study 35709798 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted PXVX0317 (2×6 μg)
Number of subjects: 415
Study 35709798 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted PXVX0317 (2×10 μg)
Number of subjects: 415
Study 35709798 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted PXVX0317 (2×20 μg)
Number of subjects: 415
Study 35709798 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted PXVX0317 (2×6 μg, accelerated)
Number of subjects: 415
Study 35709798 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted PXVX0317 (2×10 μg, accelerated)
Number of subjects: 415
Study 35709798 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted PXVX0317 (2×20 μg, accelerated)
Number of subjects: 415
Study 35709798 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted PXVX0317 (1×40 μg)
Number of subjects: 415
Study 35709798 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted PXVX0317 (2×20 μg + booster 40 μg)
Number of subjects: 415
Study 35709798 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted PXVX0317 (various doses)
Number of subjects: 415
Study 35709798 — intervention group
Group type: COMPARATOR
Intervention: Unadjuvanted PXVX0317
Number of subjects: 415
Study 35709798 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted PXVX0317
Number of subjects: 415
Study 35709798 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 415
Study 33860972 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based advance care planning intervention (5-min video)
Number of subjects: 82
Study 33860972 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 82
Study 35302207 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofol 0.4 mg/kg
Number of subjects: 176
Study 35302207 — intervention group
Group type: COMPARATOR
Intervention: Propofol 2.0 mg/kg
Number of subjects: 176
Study 33580595 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol supplementation (1,000 mg for 8 weeks)
Number of subjects: 71
Study 33580595 — intervention group
Group type: COMPARATOR
Intervention: Placebo (methyl cellulose)
Number of subjects: 71
Study 32167393 — intervention group
Group type: EXPERIMENTAL
Intervention: Idasanutlin + cytarabine
Number of subjects: 0